Does Fungitell Detect Aspergillus?
Yes, Fungitell (1→3)-β-D-glucan assay) can detect Aspergillus infections, but it is not specific for Aspergillus and has important limitations compared to galactomannan testing.
Key Diagnostic Characteristics
The Fungitell assay detects β-D-glucan (BDG), a cell wall component present in Aspergillus species along with many other fungi including Candida and Pneumocystis 1. BDG testing may be of value in supporting a diagnosis of invasive aspergillosis 1, though it functions as a pan-fungal marker rather than an Aspergillus-specific test.
Performance for Aspergillus Detection
Sensitivity vs Specificity Trade-off
- Higher sensitivity than galactomannan: BDG demonstrates 81% sensitivity for invasive aspergillosis compared to galactomannan's 49% 2
- Lower specificity than galactomannan: BDG shows only 82% specificity versus galactomannan's 97% 2
- Earlier detection possible: BDG can turn positive before galactomannan in some cases 3
Clinical Context Matters
The test performs variably depending on the clinical scenario. In hematologic malignancy patients, BDG showed higher sensitivity than galactomannan for detecting invasive aspergillosis and other mold infections 4. However, single serum sample sensitivity for Aspergillus antigen testing remains low overall 5.
Critical Limitations and Pitfalls
High False-Positive Rate
The most significant limitation is inadequate specificity 2:
- 37% false-positive rate in bacteremia patients (both Gram-positive and Gram-negative) 2
- 33% false-positive rate with β-lactam antibiotics 2
- These rates are substantially higher than galactomannan (2% for bacteremia, 29% for β-lactams)
Cannot Distinguish Fungal Pathogens
BDG cannot differentiate between:
- Aspergillus species
- Candida species
- Pneumocystis jirovecii
- Other BDG-producing fungi
Notably, BDG is absent or minimally expressed in Blastomyces, Cryptococcus, and Mucorales 6.
Guideline-Recommended Approach
When to Use BDG for Aspergillosis
According to current guidelines 1:
- Primary indication: Serum galactomannan should be performed whenever invasive aspergillosis is suspected 1
- BDG as adjunct: May provide supportive evidence when combined with other testing
- Never use BDG alone: Must be interpreted alongside galactomannan, PCR, and clinical/radiological findings
Optimal Testing Strategy
Combining BDG with galactomannan improves diagnostic performance 7:
- A composite diagnostic probability value integrating both tests achieved 73% sensitivity and 86.6% specificity
- This outperformed either test alone (P = 0.010 for BDG, P = 0.002 for GM)
- A positive Aspergillus PCR combined with positive galactomannan usually confirms the diagnosis of invasive aspergillosis, and if both negative, rules it out 1
Practical Clinical Algorithm
For suspected invasive aspergillosis in high-risk patients:
- First-line: Order serum galactomannan (more specific for Aspergillus) 1
- Add BDG: If galactomannan negative but high clinical suspicion persists
- Bronchoscopy with BAL: Perform galactomannan on BAL fluid in patients with negative serum tests but strong risk factors 8
- Molecular testing: Add Aspergillus PCR on respiratory samples and consider blood PCR in neutropenic patients 1
- Interpret together: Use negative BDG to help exclude invasive fungal disease (high NPV ~97%) 9, but positive results require confirmation
Cost-Benefit Consideration
The overall benefit of BDG for aspergillosis diagnosis remains limited due to inadequate specificity and cost 2. Its primary value lies in its high negative predictive value for excluding invasive fungal infections when combined with additional mycological testing 1.